Peptides · Peptide comparison
BPC-157 vs Nesiritide (BNP)
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
Recombinant B-type natriuretic peptide that helps your heart breathe easier by reducing fluid overload and improving blood flow during acute heart failure crises.
- Healing & Recovery
- Healing & Recovery
At a glance
Quick comparison
Efficacy
Benefit ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Rapid Symptom Relief
Fluid Management
Heart Workload Reduction
Technical data
Compound specifications
BPC-157
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1419.53 g/mol
- Half-life
- 4-6 hours
- Bioavailability
- ~100% (subcutaneous)
- CAS number
- 137525-51-0
Nesiritide (BNP)
- Molecular formula
- C143H244N50O42S4
- Molecular weight
- 3464.0 Da
- Half-life
- 18 minutes (terminal elimination half-life)
- Bioavailability
- 100% (intravenous administration)
- CAS number
- 114471-18-0
Protocols
Dosing compared
BPC-157
Subcutaneous
- 250 mcgOnce daily · 1-2 weeksA common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
- 250-500 mcgTwice daily · 4-6 weeksCommonly used range for tissue and tendon recovery in research practice [1][3].
- 500 mcgTwice daily · 6-8 weeksUpper end used in practice for more demanding acute injuries [1][3].
Nesiritide (BNP)
Intravenous
- 2 mcg/kg IV bolusSingle bolus at initiation · One-time loading doseFDA-approved Natrecor loading bolus given before the maintenance infusion [5][6]. May be omitted if hypotension risk is high.
- 0.01 mcg/kg/min continuous infusionContinuous IV infusion · Typically up to 48 hoursFDA-approved maintenance infusion following the bolus [5][6]. Hospital-only with continuous blood-pressure monitoring.
Applications
Best suited for
BPC-157
- Tendon and ligament injuries
- Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
- Gut healing
- IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
- Muscle injuries
- Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
- Joint problems
- Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
- Post-surgical recovery
- Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]
Nesiritide (BNP)
- Emergency stabilization of acute heart failure episodes
- Nesiritide (BNP) is particularly well-suited for individuals focused on emergency stabilization of acute heart failure episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
- Rapid relief of severe shortness of breath
- Nesiritide (BNP) is particularly well-suited for individuals focused on rapid relief of severe shortness of breath. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
- Short-term relief in hospital, not long-term outcome improvement
- Nesiritide's benefit is short-term: it lowers lung pressures and eases breathlessness in the first hours of treatment [5]. In the 7,141-patient ASCEND-HF trial it did not reduce 30-day death or heart-failure rehospitalization (9.4% vs 10.1%), and it is not recommended for routine use [2][5].
- Managing sudden fluid buildup in the lungs or legs
- Nesiritide (BNP) is particularly well-suited for individuals focused on managing sudden fluid buildup in the lungs or legs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Nesiritide (BNP)
Common
- Headache
- Lightheadedness
- Back pain
Uncommon
- Hypotension (low blood pressure)
- Abdominal pain
- Insomnia
Serious
- Acute kidney injury
- Severe hypotension
- Allergic reaction
Research status
Safety & evidence
BPC-157
- Evidence level
- Strong preclinical (extensive animal studies)
- FDA status
- Research compound
- Safety overview
- BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
- History of cancer
Nesiritide (BNP)
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Nesiritide (Natrecor) was FDA-approved for acutely decompensated heart failure with breathlessness at rest or minimal activity [5]. Low blood pressure is the dose-limiting side effect: 12% of patients versus 4% on placebo in long-infusion trials, and symptomatic hypotension in 7.1% versus 4.0% in the 7,141-patient ASCEND-HF trial [2][5]. When it happens it can last longer than with nitroglycerin (mean 2.2 vs 0.7 hours), because the blood-pressure effect outlasts the drug's 18-minute half-life [5]. Serum creatinine rises more often than with placebo or nitroglycerin, so kidney function is monitored during and after treatment [5]. A pooled analysis of seven trials found no increase in 30- or 180-day mortality, and the trials showed no evidence of tolerance (tachyphylaxis) to its effects [5].
Contraindications
- Persistent systolic blood pressure below 100 mmHg before treatment [5]
- Cardiogenic shock [5] or severe hypotension
- Allergy to nesiritide or any ingredients [5]
Decision guide
Which is right for you?
BPC-157
Choose BPC-157 if…
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Nesiritide (BNP)
Choose Nesiritide (BNP) if…
- Emergency stabilization of acute heart failure episodes
- Rapid relief of severe shortness of breath
- Reducing hospitalization time and improving outcomes
- Managing sudden fluid buildup in the lungs or legs